Literature DB >> 11399967

Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients.

B Zöllner1, H H Feucht, M Schröter, P Schäfer, A Plettenberg, A Stoehr, R Laufs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11399967     DOI： 10.1097/00002030-200105040-00015

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  12 in total

Review 1.  Enfuvirtide.

Authors:  Toni M Dando; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Adenovirus expressing a bioluminescence reporter gene and cMAGI cell assay for the detection of HIV-1.

Authors:  Gadi Borkow; Humberto Herman Lara; Mila Ayash-Rashkovsky; Einat Tavor; Aviva Lapidot; Zvi Bentwich; Alik Honigman
Journal:  Virus Genes       Date:  2004-10       Impact factor: 2.332

3.  The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development.

Authors:  Antonella Castagna; Priscilla Biswas; Alberto Beretta; Adriano Lazzarin
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.

Authors:  L Xu; A Pozniak; A Wildfire; S A Stanfield-Oakley; S M Mosier; D Ratcliffe; J Workman; A Joall; R Myers; E Smit; P A Cane; M L Greenberg; D Pillay
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

5.  Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.

Authors:  Chris E Baldwin; Rogier W Sanders; Yiqun Deng; Suzanne Jurriaans; Joep M Lange; Min Lu; Ben Berkhout
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  Selection of T1249-resistant human immunodeficiency virus type 1 variants.

Authors:  Dirk Eggink; Christopher E Baldwin; Yiqun Deng; Johannes P M Langedijk; Min Lu; Rogier W Sanders; Ben Berkhout
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

7.  SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide.

Authors:  Takeshi Naito; Kazuki Izumi; Eiichi Kodama; Yasuko Sakagami; Keiko Kajiwara; Hiroki Nishikawa; Kentaro Watanabe; Stefan G Sarafianos; Shinya Oishi; Nobutaka Fujii; Masao Matsuoka
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

8.  Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy.

Authors:  Vladimir A Morozov; Alexei V Morozov; Dirk Schürmann; Dirck Schürmann; Heiko Jessen; Claudia Kücherer
Journal:  Virus Genes       Date:  2007-04-18       Impact factor: 2.332

9.  Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2'F-RNA aptamers.

Authors:  Makobetsa Khati; Michael Schüman; Jamal Ibrahim; Quentin Sattentau; Siamon Gordon; William James
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors.

Authors:  Béatrice Labrosse; Jean-Louis Labernardière; Elisabeth Dam; Virginie Trouplin; Katharina Skrabal; François Clavel; Fabrizio Mammano
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.